Biotechnology News

NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced...

4Tissue raises €7 million in Series A funding and appoints Stéphanie Dupont as CEO to advance its regenerative medicine technology and clinical development

GOLDEN, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ignite Proteomics, Inc. (“Ignite” or the “Company”), a precision oncology company focused on functional proteomics, today announced it is...

Total of 618 patients randomized Topline 12-week data expected in Q1 2027 MILAN and MORRISTOWN, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:...

SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at...

Published data validates ZIP12-mediated zinc signaling as a novel driver of pulmonary vascular remodeling and supports a differentiated therapeutic approach targeting underlying disease biology Phase...

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a...

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner...

Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by...

BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA...